Home/Pipeline/Seravue® (Diagnostic Assay)

Seravue® (Diagnostic Assay)

Hepatocellular Carcinoma (HCC)

DevelopmentActive

Key Facts

Indication

Hepatocellular Carcinoma (HCC)

Phase

Development

Status

Active

Company

ImCare Biotech

About ImCare Biotech

ImCare Biotech is a US-based, private biotech company founded in 2011, targeting liver cancer and related diseases through a dual approach of diagnostics and small molecule therapeutics. The company is in the pre-clinical/development stage, leveraging a management team with strong scientific and commercial expertise from institutions like Drexel University, McKinsey, and Cisco. Its core focus is on translating proprietary research into commercial diagnostic assays and drugs, with a clear vision to become a global leader in liver disease management.

View full company profile

Therapeutic Areas

Liver Cancer Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma

Other Hepatocellular Carcinoma (HCC) Drugs

Drug	Company	Phase	Status
ADI-PEG 20 (pegargiminase)	Polaris Pharma	Phase 2/3	Active
Fostroxacitabine bralpamide (MIV-818)	Medivir	Phase 2a	Active
Nelitolimod (SD-101) via PEDD™ + systemic checkpoint inhibitors	TriSalus Life Sciences	Phase 1/2	Active, not recruiting
YntraDose	BetaGlue Therapeutics	Pre-clinical	Active
seRNA 001	SRTD biotech	Preclinical	Active
BC3402 + IMFINZI	BioCity Biopharma	Phase 1b/2	Collaboration with AstraZeneca, first patient dosed (2023)
ZW251	Zymeworks	Phase 1	Active
TTI-101	Tvardi Therapeutics	Phase 1b/2	Active